MCID: BRN022
MIFTS: 49

Bronchiectasis

Categories: Respiratory diseases

Aliases & Classifications for Bronchiectasis

MalaCards integrated aliases for Bronchiectasis:

Name: Bronchiectasis 12 29 52 42 14 69
Polynesian Bronchiectasis 12
Kartagener Syndrome 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9563
ICD10 33 J47 J47.9
ICD9CM 35 494
MeSH 42 D001987
NCIt 47 C84475
UMLS 69 C0006267

Summaries for Bronchiectasis

Disease Ontology : 12 A bronchial disease that is a chronic inflammatory condition of one or more bronchi or bronchioles marked by dilatation and loss of elasticity of the walls resulting from damage to the airway wall leading to the formation of small sacs on the bronchial wall and impairment of cilia mobility in the lung. Inflammation of the bronchial wall increases mucus secretion which serves as a breeding ground for bacteria. Bronchiectasis is caused by repeated respiratory infections, immune deficiency disorders, hereditary disorders (cystic fibrosis or primary ciliary dyskinesia), mechanical factors (inhaled object or a lung tumor) or inhaling toxic substances.

MalaCards based summary : Bronchiectasis, also known as polynesian bronchiectasis, is related to bronchiectasis with or without elevated sweat chloride 3 and bronchiectasis with or without elevated sweat chloride 2. An important gene associated with Bronchiectasis is SCNN1B (Sodium Channel Epithelial 1 Beta Subunit), and among its related pathways/superpathways are Innate Immune System and Neuropathic Pain-Signaling in Dorsal Horn Neurons. The drugs Tobramycin and Azithromycin have been mentioned in the context of this disorder. Affiliated tissues include lung, neutrophil and heart, and related phenotypes are immune system and renal/urinary system

Wikipedia : 72 Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung.... more...

Related Diseases for Bronchiectasis

Diseases related to Bronchiectasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
id Related Disease Score Top Affiliating Genes
1 bronchiectasis with or without elevated sweat chloride 3 34.2 CFTR SCNN1B
2 bronchiectasis with or without elevated sweat chloride 2 34.0 SCNN1A SCNN1B SCNN1G
3 bronchiectasis with or without elevated sweat chloride 1 33.6 CFTR SCNN1A SCNN1B SCNN1G
4 pulmonary fibrosis 30.4 SCNN1A SCNN1B SCNN1G
5 pulmonary sarcoidosis 29.6 ELANE MMP8 SERPINA1
6 pulmonary embolism 28.4 CXCL8 MBL2 TLR2
7 idiopathic bronchiectasis 12.0
8 ciliary dyskinesia-bronchiectasis 11.9
9 bronchiectasis oligospermia 11.7
10 kartagener syndrome 11.6
11 ciliary dyskinesia, primary, 1, with or without situs inversus 11.3
12 cystic fibrosis 11.2
13 primary ciliary dyskinesia 11.1
14 yellow nail syndrome 11.1
15 nontuberculous mycobacterial lung disease 10.9
16 tracheobronchomegaly 10.9
17 ciliary dyskinesia, primary, 32 10.8
18 ciliary dyskinesia, primary, 28 10.8
19 ciliary dyskinesia, primary, 27 10.8
20 ciliary dyskinesia, primary, 25 10.8
21 ciliary dyskinesia, primary, 26 10.8
22 ciliary dyskinesia, primary, 22 10.7
23 panbronchiolitis, diffuse 10.7
24 ciliary dyskinesia, primary, 12 10.7
25 ciliary dyskinesia, primary, 11 10.7
26 cutis laxa, autosomal dominant 10.7
27 ciliary dyskinesia, primary, 23 10.7
28 ciliary dyskinesia, primary, 30 10.7
29 ciliary dyskinesia, primary, 9, with or without situs inversus 10.7
30 young syndrome 10.7
31 pertussis 10.7 CFTR SCNN1G
32 long qt syndrome 13 10.6 SCNN1B SCNN1G
33 squamous blepharitis 10.6 CFTR SCNN1G
34 hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy 10.6 SCNN1A SCNN1B SCNN1G
35 immunodeficiency 14 10.6
36 ciliary dyskinesia, primary, 21 10.6
37 ciliary dyskinesia, primary, 14 10.6
38 ciliary dyskinesia, primary, 29 10.6
39 bare lymphocyte syndrome, type i 10.6
40 ciliary dyskinesia, primary, 18 10.6
41 ciliary dyskinesia, primary, 6 10.6
42 ciliary dyskinesia, primary, 19 10.6
43 cutis laxa, autosomal dominant 3 10.6
44 ciliary dyskinesia, primary, 34 10.6
45 nephronophthisis 15 10.6
46 ciliary dyskinesia, primary, 10 10.6
47 ciliary dyskinesia, primary, 16 10.6
48 cutis laxa, autosomal dominant 2 10.6
49 ciliary dyskinesia, primary, 5 10.6
50 ciliary dyskinesia, primary, 13 10.6

Comorbidity relations with Bronchiectasis via Phenotypic Disease Network (PDN): (show all 20)


Agammaglobulinemia, X-Linked 1 Anxiety Disorder
Aspergillosis Bronchitis
Bronchopneumonia Chronic Pulmonary Heart Disease
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hypothyroidism Idiopathic Interstitial Pneumonia
Lung Abscess Mitral Valve Disease
Osteoporosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Pulmonary Tuberculosis
Respiratory Failure Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Bronchiectasis:



Diseases related to Bronchiectasis

Symptoms & Phenotypes for Bronchiectasis

MGI Mouse Phenotypes related to Bronchiectasis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.81 CFTR CTSG DNAH5 DNAI1 ELANE MBL2
2 renal/urinary system MP:0005367 9.43 MBL2 SCNN1A SCNN1B SCNN1G TLR2 DNAH5
3 respiratory system MP:0005388 9.17 CFTR DNAH5 DNAI1 SCNN1A SCNN1B SCNN1G

Drugs & Therapeutics for Bronchiectasis

Drugs for Bronchiectasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 32986-56-4 5496 36294
2
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
3
Budesonide Approved Phase 4 51333-22-3 63006 5281004
4
Theophylline Approved Phase 4 58-55-9 2153
5
Amikacin Approved, Vet_approved Phase 4,Phase 1,Phase 2 37517-28-5 37768
6
Meropenem Approved, Investigational Phase 4 119478-56-7 64778 441130
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
8
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
9
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
10
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Bone Density Conservation Agents Phase 4
15 Ergocalciferols Phase 4
16 Micronutrients Phase 4
17 Trace Elements Phase 4
18 Vitamins Phase 4
19 Antibodies Phase 4,Phase 3
20 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3
21 Immunoglobulins Phase 4,Phase 3
22 Vaccines Phase 4,Phase 3
23 Anti-Asthmatic Agents Phase 4,Phase 2
24 Autonomic Agents Phase 4,Phase 2
25 Bronchodilator Agents Phase 4,Phase 2
26 Neurotransmitter Agents Phase 4
27 Peripheral Nervous System Agents Phase 4,Phase 2
28 Respiratory System Agents Phase 4,Phase 2
29 Vasodilator Agents Phase 4
30 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
31 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
32 Antioxidants Phase 4
33 Protective Agents Phase 4,Phase 1
34 Adrenergic Agents Phase 4
35 Adrenergic Agonists Phase 4
36 Adrenergic beta-2 Receptor Agonists Phase 4
37 Adrenergic beta-Agonists Phase 4
38 Anti-Allergic Agents Phase 4,Phase 2
39 Anti-Inflammatory Agents Phase 4,Phase 2
40 Dermatologic Agents Phase 4,Phase 2
41
Fluticasone Phase 4,Phase 2 90566-53-3, 80474-14-2 62924 22833648
42 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4
43 glucocorticoids Phase 4
44 Hormone Antagonists Phase 4
45 Hormones Phase 4
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
47
Salmeterol xinafoate Phase 4 94749-08-3 56801
48 Formoterol Fumarate Phase 4
49 Phosphodiesterase Inhibitors Phase 4
50 Purinergic P1 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 224)

id Name Status NCT ID Phase Drugs
1 A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis Unknown status NCT01677403 Phase 4 Tobramycin;Saline
2 Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis Unknown status NCT02507843 Phase 4 Cholecalciferol;Placebo
3 Polysaccharide Antibody Response Study Unknown status NCT02429531 Phase 4
4 Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis Completed NCT02782312 Phase 4 ICS+LABA
5 Is Regular Chest Physiotherapy an Effective Treatment in Severe, Non Cystic Fibrosis Bronchiectasis? Completed NCT00816309 Phase 4
6 The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis Completed NCT01769898 Phase 4 Formoterol-budesonide;Theophylline;Placebo
7 Efficacy of Azithromycin in Treatment of Bronchiectasis Completed NCT02107274 Phase 4 Azithromycin;Placebo for Azithromycin
8 Atorvastatin in Bronchiectasis in Patients With Pseudomonas Aeruginosa Completed NCT01299194 Phase 4 ATORVASTATIN
9 The Effect of Theophylline in the Treatment of Bronchiectasis Completed NCT01684683 Phase 4 Theophylline;Placebo(for Theophylline)
10 Pulmonary Rehabilitation in Non Cystic Fibrosis Bronchiectasis Completed NCT00868075 Phase 4
11 A Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis Completed NCT01299181 Phase 4 Atorvastatin
12 Long Term Nebulised Gentamicin in Patients With Bronchiectasis Completed NCT00749866 Phase 4 Gentamicin;Saline
13 Effectiveness and Safety of Inhaling Hypertonic Saline in Patients With Chronic Obstructive Pulmonary Disease Completed NCT00639236 Phase 4
14 Efficacy of Temporary Positive Expiratory Pressure (TPEP) in Chronic Hypersecretion Completed NCT00700388 Phase 4
15 Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations Recruiting NCT02047773 Phase 4 Colomycin;Meropenem
16 Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis Recruiting NCT02509091 Phase 4 Bronchoalveolar Lavage and Local Amikacin Injection
17 Comparisons of Inhaled LAMA or ICS+LABA for COPD With Bronchiectasis Recruiting NCT02546297 Phase 4 Symbicort;Tiotropium Bromide
18 Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials Recruiting NCT03147443 Phase 4 Individualized Decoction;placebo;Tested drug minus heat-clearing herbs
19 Hospitalised Pneumonia With Extended Treatment (HOPE) Study Recruiting NCT02783859 Phase 4 Amoxicillin-clavulanic Acid;Placebo (for Amoxicillin-clavulanic Acid)
20 Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis Active, not recruiting NCT02081963 Phase 4 Amikacin;Normal saline
21 Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis Active, not recruiting NCT02088216 Phase 4 N-acetylcysteine;Placebo
22 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Active, not recruiting NCT01830959 Phase 4 Roflumilast;Placebo
23 VX-770 for the Treatment of Chronic Bronchitis Not yet recruiting NCT03251911 Phase 4 Ivacaftor (VX-770)
24 Bronchiectasis and Long Term Azithromycin Treatment Unknown status NCT00415350 Phase 3 Azithromycin
25 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3 tranexamic acid;tranexamic acid
26 Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis Completed NCT02104245 Phase 3 Pulmaquin;Placebo
27 Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Completed NCT01764841 Phase 3 Ciprofloxacin DPI (BAYQ3939);Placebo
28 Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) Completed NCT02106832 Phase 3 Ciprofloxacin (BAYQ3939) dry powder for inhalation;Ciprofloxacin (BAYQ3939) dry powder for inhalation;Placebo;Placebo
29 Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis Completed NCT00669331 Phase 3 Inhaled mannitol;Matched control
30 Safety and Efficacy of Bronchitol in Bronchiectasis Completed NCT00277537 Phase 3 Mannitol;placebo
31 The Long Term Effect of Inhaled Hypertonic Saline (6%) in Patients With Non Cystic Fibrosis Bronchiectasis Completed NCT00484263 Phase 3 Hypertonic saline 6% -
32 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Completed NCT01313624 Phase 3 AZLI;Placebo
33 Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis Completed NCT01314716 Phase 3 AZLI;Placebo
34 Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis Completed NCT01515007 Phase 3 Ciprofloxacin
35 Efficacy and Safety Study of a Percussion Device to Mobilise Sputum From Respiratory Passage Completed NCT01480882 Phase 2, Phase 3
36 Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT) Completed NCT00656409 Phase 3 Conjugated pneumococcal vaccine (Prevenar)
37 EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection Completed NCT00105183 Phase 3
38 Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher Completed NCT00380315 Phase 3 AG1321001(drug)
39 Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF Completed NCT01641822 Phase 3 AZLI;Placebo to match AZLI;Tobramycin inhalation solution
40 Prevention of OM-85 on Bronchiectasis Exacerbation Recruiting NCT01968421 Phase 3 OM-85
41 Prevention of Bronchiectasis in Infants With Cystic Fibrosis Recruiting NCT01270074 Phase 3 Azithromycin;Placebo control
42 Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis Recruiting NCT02657473 Phase 2, Phase 3 tobramycin inhalation solution;Saline 0.9% inhalation solution
43 Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium Recruiting NCT03093974 Phase 3 Colistimethate Sodium;Saline Solution
44 An Open Label Trial of Azithromycin in Chronic Productive Cough Recruiting NCT02196493 Phase 3 Azithromycin
45 The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis Active, not recruiting NCT02531984 Phase 3 Azithromycin
46 Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization Active, not recruiting NCT01973998 Phase 3 Roflumilast;Placebo
47 Hypertonic Saline (6%) Versus Isotonic Saline (0.9%) in Bronchiectasis Unknown status NCT01112410 Phase 2
48 Phase2, Single Group, Open Clinical Trial to Evaluate the Efficacy and Safety of Roflumilast in Symptomatic Bronchiectasis Patients Unknown status NCT01580748 Phase 2 Roflumilast
49 Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis Completed NCT02035488 Phase 1, Phase 2 Tobramycin
50 Physical Capacity in Patients With Bronchiectasis Before and After Rehabilitation Program Completed NCT02208830 Phase 1, Phase 2

Search NIH Clinical Center for Bronchiectasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: bronchiectasis

Genetic Tests for Bronchiectasis

Genetic tests related to Bronchiectasis:

id Genetic test Affiliating Genes
1 Bronchiectasis 29

Anatomical Context for Bronchiectasis

MalaCards organs/tissues related to Bronchiectasis:

39
Lung, Neutrophil, Heart, Testes, Colon, Bone, Liver

Publications for Bronchiectasis

Articles related to Bronchiectasis:

(show top 50) (show all 788)
id Title Authors Year
1
Microbial Dysbiosis in Bronchiectasis and Cystic Fibrosis. ( 28069292 )
2017
2
Successful treatment of pulmonary nocardiosis with fluoroquinolone in bronchial asthma and bronchiectasis. ( 28352469 )
2017
3
The quantitative link of lung clearance index to bronchial segments affected by bronchiectasis. ( 28866642 )
2017
4
Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis. ( 28828295 )
2017
5
The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. ( 28808486 )
2017
6
De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy. ( 28889888 )
2017
7
Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways. ( 28516246 )
2017
8
Differences of lung microbiome in patients with clinically stable and exacerbated bronchiectasis. ( 28829833 )
2017
9
Two cases of non-cystic fibrosis (CF) bronchiectasis with allergic bronchopulmonary aspergillosis. ( 28053855 )
2017
10
Improving the management of people with bronchiectasis in Saudi: A new beginning. ( 28808485 )
2017
11
Bronchiectasis Complicating Lung Volume Reduction Coil Treatment. ( 28889896 )
2017
12
Sugar coating bronchiectasis. ( 28070016 )
2017
13
The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration. ( 28894479 )
2017
14
Editorial: Chronic Suppurative Lung Disease and Bronchiectasis in Children and Adolescents. ( 28929095 )
2017
15
Does home-based pulmonary rehabilitation improve functional capacity, peripheral muscle strength and quality of life in patients with bronchiectasis compared to standard care? ( 28869119 )
2017
16
Molecular epidemiology of Pseudomonas aeruginosa in an unsegregated bronchiectasis cohort sharing hospital facilities with a cystic fibrosis cohort. ( 28844058 )
2017
17
Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD. ( 28919731 )
2017
18
Residual volume/total lung capacity ratio confers limited additive significance to lung clearance index for assessment of adults with bronchiectasis. ( 28886040 )
2017
19
Comparing accelerometer, pedometer and a questionnaire for measuring physical activity in bronchiectasis: a validity and feasibility study? ( 28088206 )
2017
20
Serum Albumin and Disease Severity of Non-Cystic Fibrosis Bronchiectasis. ( 28512120 )
2017
21
Diffuse bronchiectasis as the primary manifestation of endobronchial sarcoidosis. ( 27896060 )
2017
22
Diagnosis of bronchiectasis and airway wall thickening in children with cystic fibrosis: Objective airway-artery quantification. ( 28523349 )
2017
23
Promoting Physical Activity Using The Internet: Is It Feasible And Acceptable For Patients With Chronic Obstructive Pulmonary Disease (COPD) And Bronchiectasis? ( 28952865 )
2017
24
European Respiratory Society guidelines for the management of adult bronchiectasis. ( 28889110 )
2017
25
Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. ( 28952156 )
2017
26
The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. ( 28863927 )
2017
27
Ochroconis gallopava bronchitis mimicking haemoptysis in a patient with bronchiectasis. ( 28884072 )
2017
28
Is treatment of serological ABPA similar to that of ABPA with bronchiectasis? ( 28888259 )
2017
29
Anxiety and depression in adult outpatients with bronchiectasis: Associations with disease severity and health-related quality of life. ( 28842946 )
2017
30
Nasal Nitric Oxide Measurement and a Modified PICADAR Score for the Screening of Primary Ciliary Dyskinesia in Adults with Bronchiectasis. ( 28783864 )
2017
31
The factors affecting survival in patients with bronchiectasis. ( 28081336 )
2016
32
Enlarged Dural Sac in Idiopathic Bronchiectasis Implicates Heritable Connective Tissue Gene Variants. ( 27409985 )
2016
33
Bronchiectasis in yellow nail syndrome. ( 27551950 )
2016
34
Asthma and bronchiectasis exacerbation. ( 27076584 )
2016
35
Factors related to depression and anxiety in adults with bronchiectasis. ( 27920537 )
2016
36
Macrolides for Clinically Significant Bronchiectasis in Adults: Who Should Receive this Treatment? ( 27591924 )
2016
37
Clinical characteristics of pulmonary hypertension in bronchiectasis. ( 27527360 )
2016
38
Risk factors for requiring intravenous antibiotic therapy in hospital and 30-day readmission for exacerbations of bronchiectasis. ( 27081209 )
2016
39
Clinical phenotypes in bronchiectasis: right on track to develop precision medicine in respiratory diseases. ( 27084830 )
2016
40
Prevalence of Osteopenia and Osteoporosis in Patients with Noncystic Fibrosis Bronchiectasis. ( 27911973 )
2016
41
Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. ( 27516225 )
2016
42
Adult Bronchiectasis Patients: A First Look at the United States Bronchiectasis Research Registry. ( 27889361 )
2016
43
Recommendations for aetiological diagnosis of bronchiectasis. ( 27134122 )
2016
44
Changing epidemiology of non-cystic fibrosis bronchiectasis. ( 27922232 )
2016
45
Evaluation of a novel information resource for patients with bronchiectasis: study protocol for a randomised controlled trial. ( 27107959 )
2016
46
Eradication of Mycobacterium abscessus Pulmonary Infection in a Child With Idiopathic Bronchiectasis. ( 27896296 )
2016
47
Assessment of the quantity of microorganisms associated with bronchiectasis in saliva, sputum and nasal lavage after periodontal treatment: a study protocol of a randomised controlled trial. ( 27084279 )
2016
48
Giant Aortopulmonary Collateral Artery in an Adult with Bronchiectasis. ( 27127447 )
2016
49
Cystic Bronchiectasis Imitating Pulmonary Aspergilloma. ( 27569246 )
2016
50
Impulse Oscillometry and Spirometry Small-Airway Parameters in Mild to Moderate Bronchiectasis. ( 27484107 )
2016

Variations for Bronchiectasis

Expression for Bronchiectasis

Search GEO for disease gene expression data for Bronchiectasis.

Pathways for Bronchiectasis

GO Terms for Bronchiectasis

Cellular components related to Bronchiectasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 BPI CTSG CXCL8 ELANE MBL2 MMP8
2 extracellular exosome GO:0070062 9.96 BPI CFTR CTSG ELANE MPO SCNN1A
3 cell surface GO:0009986 9.85 CFTR CTSG ELANE MBL2 TLR2
4 extracellular space GO:0005615 9.81 BPI CTSG CXCL8 ELANE MBL2 MMP8
5 apical plasma membrane GO:0016324 9.78 CFTR SCNN1A SCNN1B SCNN1G
6 secretory granule GO:0030141 9.61 CTSG ELANE MPO
7 specific granule lumen GO:0035580 9.54 BPI ELANE MMP8
8 outer dynein arm GO:0036157 9.4 DNAH5 DNAI1
9 sodium channel complex GO:0034706 9.13 SCNN1A SCNN1B SCNN1G
10 azurophil granule lumen GO:0035578 9.02 BPI CTSG ELANE MPO SERPINA3

Biological processes related to Bronchiectasis according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.8 CTSG ELANE MPO TLR2
2 sodium ion transport GO:0006814 9.75 SCNN1A SCNN1B SCNN1G
3 defense response to Gram-positive bacterium GO:0050830 9.72 CTSG MBL2 TLR2
4 defense response to bacterium GO:0042742 9.72 BPI CTSG ELANE MBL2 MPO
5 sodium ion transmembrane transport GO:0035725 9.71 SCNN1A SCNN1B SCNN1G
6 extracellular matrix disassembly GO:0022617 9.69 CTSG ELANE MMP8
7 antimicrobial humoral response GO:0019730 9.63 BPI CTSG ELANE
8 sensory perception of taste GO:0050909 9.61 SCNN1A SCNN1B SCNN1G
9 acute-phase response GO:0006953 9.58 MBL2 SERPINA1 SERPINA3
10 outer dynein arm assembly GO:0036158 9.57 DNAH5 DNAI1
11 response to molecule of bacterial origin GO:0002237 9.56 CXCL8 TLR2
12 neutrophil degranulation GO:0043312 9.56 BPI CTSG ELANE MMP8 MPO SERPINA1
13 defense response to fungus GO:0050832 9.54 CTSG ELANE MPO
14 positive regulation of immune response GO:0050778 9.52 CTSG ELANE
15 response to yeast GO:0001878 9.48 ELANE MPO
16 negative regulation of growth of symbiont in host GO:0044130 9.46 CTSG ELANE MBL2 MPO
17 sodium ion homeostasis GO:0055078 9.43 SCNN1A SCNN1B SCNN1G
18 multicellular organismal water homeostasis GO:0050891 8.92 CFTR SCNN1A SCNN1B SCNN1G

Molecular functions related to Bronchiectasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.46 CTSG ELANE MBL2 MMP8
2 WW domain binding GO:0050699 9.13 SCNN1A SCNN1B SCNN1G
3 ligand-gated sodium channel activity GO:0015280 8.8 SCNN1A SCNN1B SCNN1G

Sources for Bronchiectasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....